with this condition (HH that measure more than 10cm) are more susceptible to present symptoms and complications [2]. EpidemiologyIt is the second most common tumor in the liver after metastasis and represents 73% of all benign liver tumors, although its frequency in autopsy studies is less than 0.4% [2,3], some studies indicate that its prevalence and incidence can reach 20% and 7% of the general population, respectively [3,4].Generally, these tumors affect adult women in their third and fifth decade of life, mainly multiparous women. However, it is important to mention that it can occur at any age of life [3,5]. The female to male ratio ranging from 3: 1 to 5: 1 according to preview studies [2][3][4][5]. EtiopathogenesisThe etiopathogenesis of HH is not yet fully understood, however, it has been postulated that they are vascular malformations or hamartomas of congenital origin that are produced secondary to an intense ectasia due to hypertrophy or vascular hyperplasia [5]. There are different theories about the genetic component: Moser C et al. [6] reported the case of an Italian family, where three female members in three successive generations had symptoms related with HH and two other relatives showed asymptomatic HH on ultrasound. Likewise, Diez Redondo P et al. [7] reported a family in which six members from three successive generations presented HH, suggesting that a clear family component might exist.Women's disease preference may be explain by the expressiveness of a presumed "HH gene", proliferate factors are the condition of been a woman, increased production of female sex hormones (during puberty or pregnancy) or the use of oral contraceptives. In fact, there are reports of growth and rupture of these tumors during pregnancy or in menopausal women undergoing hormonal treatment [2,5]. Clinical FeaturesIn most cases HH do not present symptoms, they are most likely to be discovered incidentally during imaging studies for other unrelated conditions and if they present symptoms, they are nonspecific common symptoms to many other diseases of digestive origin (nausea, pain, abdominal distention, early satiety) [4]. Some authors report that there is a close relationship between tumor size and the presence of symptoms, 40% of the patients present symptoms in cases that hemangiomas measure more than 4 cm and 90% in cases that hemangiomas measure more than 10 cm denominated giant hepatic hemangiomas (HHG). Mainly symptoms are upper abdominal pain usually mild, but that can become severe in cases of thrombosis or bleeding within the lesion, which stretches and inflames Glisson's capsule [5].Physical examination is usually normal without significant findings, only rarely the hemangioma is presented as a large abdominal mass and an arterial murmur in the upper quadrant (Figure 1). Complications will depend on the location of the tumor and is generally present in cases of giant hemangiomas (HHG). It has been described circulatory shock and hemoperitoneum with Review ArticleGastroenterol Hepatol Open Access 2017, 7...
Background Reports suggest that Latin American and Caribbean (LAC) countries have not reduced leukemia mortality compared to high-income countries. However, updated trends remain largely unknown in the region. Given that leukemia is the leading cause of cancer-related death in LAC children, we evaluated mortality trends in children (0-14y) from 15 LAC countries for the period 2000–2017 and predicted mortality to 2030. Methods We retrieved cancer mortality data using the World Health Organization Mortality Database. Mortality rates (standardized to the world standard SEGI population) were analyzed for 15 LAC countries. We evaluated the average mortality rates for the last 5 years (2013–2017). Joinpoint regression analysis was used to evaluate leukemia mortality trends and provide an estimated annual percent change (EAPC). Nordpred was utilized for the calculation of predictions until 2030. Results Between 2013 and 2017, the highest mortality rates were reported in Venezuela, Ecuador, Nicaragua, Mexico, and Peru. Upward mortality trends were reported in Nicaragua (EAPC by 2.9% in boys, and EAPC by 2.0% in girls), and Peru (EAPC by 1.4% in both sexes). Puerto Rico experienced large declines in mortality among both boys (EAPC by − 9.7%), and girls (EAPC by − 6.0%). Leukemia mortality will increase in Argentina, Ecuador, Guatemala, Panama, Peru, and Uruguay by 2030. Conclusion Leukemia mortality is predicted to increase in some LAC countries by 2030. Interventions to prevent this outcome should be tailor to reduce the socioeconomic inequalities and ensure universal healthcare coverage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.